ALK and non-small cell lung carcinoma: Acquired resistance to Anaplastic lymphoma kinase (ALK) TKIs such as crizotinib has been described in patients with NSCLC positive for the echinoderm microtubule-associated protein–like 4 (EML4)–ALK fusion protein.